The FLAURA trial demonstrated that the third-generation TKI osimertinib shows superior efficacy compared to standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC [28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.